Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

Pfaller, Michael A.; Woosley, Leah N.; Messer, S. A.; Jones, Ronald N.; Castanheira, Mariana

doi:10.1007/s11046-012-9551-x

Cited by 72 publications

(80 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Isolates were submitted to JMI Laboratories (North Liberty, IA), where the identification was confirmed by morphological, biochemical, and molecular methods (31)(32)(33)(34). Yeast isolates were subcultured and screened using CHROMagar Candida (Becton, Dickinson, Sparks, MD) to ensure purity and to differentiate Candida albicans/Candida dubliniensis, Candida tropicalis, and Candida krusei.…”

Section: Methodsmentioning

confidence: 99%

“…(31,34). All mold isolates were subcultured and analyzed by ITS sequencing followed by specific molecular species identification within genera, i.e., ␤-tubulin for Aspergillus spp., translation elongation factor (TEF) for Fusarium spp., and 28S subunit for all other genera of molds (34). Nucleotide sequences were examined using Lasergene software (DNA Star, Madison, WI) and then compared to database sequences using BLAST (http://blast.ncbi.nlm.nih .gov).…”

Section: Methodsmentioning

confidence: 99%

“…Nucleotide sequences were examined using Lasergene software (DNA Star, Madison, WI) and then compared to database sequences using BLAST (http://blast.ncbi.nlm.nih .gov). Fusarium isolates were analyzed for TEF sequences using the Fusarium-ID database (http://www.isolate.fusariumdb.org/index.php) and the Fusarium multilocus sequence typing (MLST) database (http://www .cbs.knaw.nl/fusarium/BiolomicsInfo.aspx) (34) Antifungal susceptibility testing. All yeast isolates were tested for in vitro susceptibility to isavuconazole (11 dilutions; range, 0.008 to 8 g/ ml), posaconazole (11 dilutions; range, 0.008 to 8 g/ml), voriconazole (11 dilutions; range, 0.008 to 8 g/ml), fluconazole (12 dilutions; range, 0.06 to 128 g/ml), anidulafungin (12 dilutions; range, 0.008 to 16 g/ ml), caspofungin (12 dilutions; range, 0.008 to 16 g/ml), and micafungin (12 dilutions; range, 0.008 to 16 g/ml) using CLSI BMD methods (35).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

et al. 2013

Self Cite

View full text Add to dashboard Cite

Isavuconazole is a new broad-spectrum triazole with a favorable pharmacokinetic and safety profile. We report the MIC distributions for isavuconazole and 111 isolates of Candida (42 Candida albicans, 25 Candida glabrata, 22 Candida parapsilosis, 14 Candida tropicalis, and 8 Candida krusei isolates), as determined by Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution (BMD) methods. Also, the relative activities of isavuconazole, itraconazole, fluconazole, posaconazole, voriconazole, and the three echinocandins were assessed against a recent (2011) global collection of 1,358 isolates of Candida spp., 101 of Aspergillus spp., 54 of non-Candida yeasts, and 21 of non-Aspergillus molds using CLSI BMD methods. The overall essential agreement (EA) (؎2 log 2 dilutions) between the CLSI and EUCAST methods was 99.1% (EA at ؎1 log 2 dilution, 90.1% [range, 80.0 to 100.0%]). The activities of isavuconazole against the larger collection of Candida spp. and Aspergillus spp. were comparable to those of posaconazole and voriconazole; the MIC 90 values for isavuconazole, posaconazole, and voriconazole against Candida spp. were 0.5, 1, and 0.25 g/ml and against Aspergillus spp. were 2, 1, and 1 g/ml, respectively. Isavuconazole showed good activities against Cryptococcus neoformans (MIC 90 , 0.12 g/ml) and other non-Candida yeasts (MIC 90 , 1 g/ml) but was less potent against non-Aspergillus molds (MIC 90 , >8 g/ml). Isavuconazole MIC values for three mucormycete isolates were 4, 1, and 2 g/ml, whereas all three were inhibited by 1 g/ml posaconazole. Isavuconazole demonstrates broad-spectrum activity against this global collection of opportunistic fungi, and the CLSI and EUCAST methods can be used to test this agent against Candida, with highly comparable results.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Vitek 2 system, using the ID-YST (fluorimetric) card and the newly developed YST (colorimetric) card, incorporates a database that has been unmodified since 2000, with 52 identifiable yeast species. It is noteworthy that the systems' databases have been progressively updated to cover taxa of common and uncommon clinical species, but their performance should be continually monitored to determine whether these systems are actually capable of keeping up with the appearance of rare or novel pathogenic species (18,19) and possibly with the geographic or source variations of clinical isolates (20).…”

mentioning

confidence: 99%

Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy

et al. 2015

View full text Add to dashboard Cite

Accurate identification of pathogenic species is important for early appropriate patient management, but growing diversity of infectious species/strains makes the identification of clinical yeasts increasingly difficult. Among conventional methods that are commercially available, the API ID32C, AuxaColor, and Vitek 2 systems are currently the most used systems in routine clinical microbiology. We performed a systematic review and meta-analysis to estimate and to compare the accuracy of the three systems, in order to assess whether they are still of value for the species-level identification of medically relevant yeasts. After adopting rigorous selection criteria, we included 26 published studies involving Candida and non-Candida yeasts that were tested with the API ID32C (674 isolates), AuxaColor (1,740 T he epidemiology of yeast infections, particularly those involving the bloodstream (i.e., fungemia) or other normally sterile sites, continues to evolve throughout the world (1), likely due to the diversity of susceptible hosts, including mainly patients undergoing transplantations or receiving treatment for underlying malignant diseases (2). Prophylactic use of antifungals has also contributed to alterations in the patterns of such infections, leading to increases in the incidence of non-albicans Candida species, compared to Candida albicans (3-6). Although the latter species is the most frequently isolated yeast in hospital settings (7), the emergence of less-common or "cryptic" non-albicans Candida species, as well as uncommon yeasts such as Rhodotorula, Geotrichum, Pichia, Malassezia, Saccharomyces, and cryptococci other than Cryptococcus neoformans (8), poses a threat due to their potential to develop antifungal resistance (9-12) or their intrinsically decreased susceptibility to one or more antifungal agents (13-15). As differences in antifungal drug susceptibilities can exist not only among genera but also among members of the same genus or species complex (8), accurate species identification is important for initiating early effective antifungal therapy, especially when susceptibility testing results are not promptly available.As simple, rapid, reliable alternatives to traditional methods based on the Wickerham assimilation/fermentation patterns (16), manual (e.g., AuxaColor [Bio-Rad, Marnes-la-Coquette, France]) and automated (i.e., Vitek 2 [bioMérieux, Marcy l'Etoile, France]) commercial identification systems are currently being used in clinical microbiology laboratories, but their ability to identify yeast isolates to the species level is dependent on the types and numbers of biochemical (carbohydrate/enzyme) substrates tested (17). Although with a limited database of only 26 taxa/species (updated to include 33 yeast species in a newer version of the system [AuxaColor 2], which was launched in 2002), the AuxaColor system uses colorimetric tests for assimilation substrates,

show abstract

“…More recently, bioinformatic methods based on sequencing parts of the genome have been used to analyze fungi or fungal extracts by introducing chemotaxonomical markers. 2,3 It is necessary to introduce a novel monitoring method that can accurately and efficiently identify fungal species. Spectroscopic analysis, which requires little sample preparation procedures, would meet the purpose of rapid analysis or identification of fungi.…”

mentioning

confidence: 99%

Chemotaxonomic Raman Spectroscopy Investigation of Ascomycetes and Zygomycetes

Lee¹,

Cho²,

Ochir³

et al. 2013

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

Cited by 72 publications

References 31 publications

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy

Chemotaxonomic Raman Spectroscopy Investigation of Ascomycetes and Zygomycetes

Contact Info

Product

Resources

About